Previous 10 | Next 10 |
home / stock / lly / lly articles
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this artic...
Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S...
In a significant development, Medicare may extend coverage for Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (sem...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter. "We ...
Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash p...
Eli Lilly And Co’s (NYSE:LLY) much-in-demand weight-loss drug Zepbound (tirzepatide) surged ahead with 77,590 new prescriptions in the U...
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return o...
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization...
As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medicat...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...